AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma

Vaarwerk, Bas; Hol, M.; Schoot, Reineke A.; Breunis, Willemijn B.; Win, Maartje M. L. de; Westerveld, Henrike; Fajardo, Raquel Dávila; Saeed, Peerooz; Brekel, Michiel W. M. van den; Pieters, Bradley R.; Strackee, Simon D.; Smeele, Ludi E.; Merks, Johannes H. M.

doi:10.1016/j.radonc.2018.10.036

Cited by 20 publications

(54 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between the 1970s and the early 2000s, results from a number of European RMS trials reported relapse rates of 31% [4], 29% [5], and 36% [6] for patients who presented initially with non-metastatic disease treated on the Italian RMS studies (RMS 79, 88, 96), the Cooperative Weichteilsarkom Studiengruppe (CWS) studies (CWS 81,86,91,96), and the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal Tumor (MMT) studies (MMT-84, 89, 95), respectively. Results from the North American Intergroup Rhabdomyosarcoma Study (IRS) I, which was conducted during the early part of this period, reported a similar relapse rate of 34% in all newly diagnosed RMS patients, including those with both localized and metastatic disease at diagnosis [7].…”

Section: Rms Relapse: a Historical Perspectivementioning

confidence: 99%

“…For patients with localized recurrence who are unable to undergo surgical intervention at relapse, there is some evidence that radiation alone may also be beneficial [82,85]. For patients who lack an option for conventional re-irradiation at recurrence due to prior radiotherapy, a common issue for patients with primary tumors arising in the head and neck sites, site-specific mixed local control approaches, for example, the use of salvage AMORE (Ablative surgery, MOuld technique brachytherapy and surgical REconstruction) treatment, may be feasible and have been associated with promising results [86].…”

Section: Local Control In Relapsed Rmsmentioning

confidence: 99%

See 1 more Smart Citation

Relapsed Rhabdomyosarcoma

Heske

Mascarenhas

2021

JCM

View full text Add to dashboard Cite

Relapsed rhabdomyosarcoma (RMS) represents a significant therapeutic challenge. Nearly one-third of patients diagnosed with localized RMS and over two-thirds of patients with metastatic RMS will experience disease recurrence following primary treatment, generally within three years. Clinical features at diagnosis, including primary site, tumor invasiveness, size, stage, and histology impact likelihood of relapse and prognosis post-relapse. Aspects of initial treatment, including extent of surgical resection, use of radiotherapy, and chemotherapy regimen, are also associated with post-relapse outcomes, as are features of the relapse itself, including time to relapse and extent of disease involvement. Although there is no standard treatment for patients with relapsed RMS, several general principles, including tissue biopsy confirmation of diagnosis, assessment of post-relapse prognosis, determination of the feasibility of additional local control measures, and discussion of patient goals, should all be part of the approach to care. Patients with features suggestive of a favorable prognosis, which include those with botryoid RMS or stage 1 or group I embryonal RMS (ERMS) who have had no prior treatment with cyclophosphamide, have the highest chance of achieving long-term cure when treated with a multiagent chemotherapy regimen at relapse. Unfortunately, patients who do not meet these criteria represent the majority and have poor outcomes when treated with such regimens. For this group, strong consideration should be given for enrollment on a clinical trial.

show abstract

Section: Rms Relapse: a Historical Perspectivementioning

confidence: 99%

Section: Local Control In Relapsed Rmsmentioning

confidence: 99%

Relapsed Rhabdomyosarcoma

Heske

Mascarenhas

2021

JCM

View full text Add to dashboard Cite

show abstract

“…Compared with external beam RT, brachytherapy has a steep dose gradient and minimizes normal tissue exposure and thus has the potential to reduce long‐term radiation‐induced toxicity. For most tumors, brachytherapy is performed after maximal surgical resection, thus improving the potential for tumor control compared with just high‐dose external RT alone 53‐58 . In a report from the Memorial Sloan Kettering Cancer Center (MSKCC), 75 children with a variety of sarcomas, including rhabdomyosarcoma and Ewing sarcoma, underwent high dose rate intraoperative brachytherapy (4‐17.5 Gy prescribed to depth of 5 mm from applicator surface) after surgical resection.…”

Section: Brachytherapymentioning

confidence: 99%

“…Mold brachytherapy was delivered using iridium‐192 brachytherapy (40‐50 Gy to a depth of 5 mm using low dose or pulse dose rate brachytherapy). The local control rate was 67%, and the five‐year OS was 54% 58 . A recent report described the clinical outcomes in 237 girls with vagina/uterine rhabdomyosarcoma derived from 13 clinical trials from four cooperative groups including COG, SIOP Malignant Mesenchymal tumor group (SIOPMMT), Italian Cooperative Sarcoma Study Group (ICG), and European pediatric soft‐tissue sarcoma group (EpSSG).…”

Section: Brachytherapymentioning

confidence: 99%

See 1 more Smart Citation

Radiosurgery, reirradiation, and brachytherapy

Prasad

Vern-Gross

Wolden

2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Radiosurgery and brachytherapy are potentially useful treatment techniques that are sparingly applied in pediatric oncology. They are often used in the setting of reirradiation for recurrent or metastatic tumors. Reirradiation in children with recurrent tumors is complicated by the tolerance of critical organs and the potential risks for overall long‐term dose‐dependent complications. We review the current literature available in support of reirradiation and the use of radiosurgery and brachytherapy in pediatric patients.

show abstract

Treatment of nasolabial fold rhabdomyosarcoma in children: A single‐institution experience

Zhang,

Sun,

et al. 2024

Head & Neck

View full text Add to dashboard Cite

ObjectivesTo summarize the clinical characteristics and prognosis of children with nasolabial fold rhabdomyosarcoma (RMS).MethodsRetrospective review of children treated for nasolabial fold RMS from January 2014 to September 2019.ResultsOf 21 patients with nasolabial fold RMS, 90.48% were alveolar subtype, in which PAX3/7‐FOXO1 fusion positive accounted for 87.5%. Ten patients (47.62%) had nodals invasion. Almost all patients received comprehensive treatment (chemotherapy [100%], radiation therapy [100%], and surgery [95.24%]). The median follow‐up time was 34.3 months. The 3‐year overall survival (OS) and event‐free survival (EFS) was 67.7% ± 14.1% and 42.1% ± 13.5%, respectively. Four patients had regional lymph node relapse (NR), all in the ipsilateral submandibular lymph node region.ConclusionMajority of the patients with RMS in the nasolabial fold area were alveolar subtype and had positive PAX3/7‐FOXO1 gene fusion. In addition, the nasolabial fold RMS had a high probability of regional lymph node metastasis in the submandibular area. To maintain the facial aesthetics and functions, the surgical area for nasolabial fold RMS is often very conservative and restricted. This could be one of the contributors for the poor prognosis of nasolabial fold RMS beside its worse pathological subtype and gene fusion.

show abstract

AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma

Cited by 20 publications

References 22 publications

Relapsed Rhabdomyosarcoma

Relapsed Rhabdomyosarcoma

Radiosurgery, reirradiation, and brachytherapy

Treatment of nasolabial fold rhabdomyosarcoma in children: A single‐institution experience

Contact Info

Product

Resources

About